Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the
availability over the past 15 years of multiple drugs interfering with the endothelin, nitric …

Summary Each year, the American Heart Association (AHA), in conjunction with the Centers
for Disease Control and Prevention, the National Institutes of Health, and other government …

Pulmonary hypertension encompasses a range of conditions directly or indirectly leading to
elevated pressures within the pulmonary arteries. Five main groups of pulmonary …

Pulmonary hypertension is defined as a resting mean pulmonary artery pressure of 25 mm
Hg or above. This review deals with pulmonary arterial hypertension (PAH), a type of …

6.2. 2. Wydolność wysiłkowa......................... 1147 6.2. 3. Markery biochemiczne........................
1147 6.2. 4. Kompleksowa ocena rokownicza i oszacowanie ryzyka........................... 1148 6.2 …

Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

Pulmonary hypertension is a substantial global health issue. All age groups are affected with
rapidly growing importance in elderly people, particularly in countries with ageing …

Background In a phase 2 trial, selexipag, an oral selective IP prostacyclin-receptor agonist,
was shown to be beneficial in the treatment of pulmonary arterial hypertension. Methods In …

Background Data on the effect of initial combination therapy with ambrisentan and tadalafil
on long-term outcomes in patients with pulmonary arterial hypertension are scarce. Methods …

In the past 2 decades, major changes have occurred in the epidemiological and treatment
landscape of pulmonary arterial hypertension (PAH). Previously regarded as a disease of …